BIO 2011 report: Australian biotechnology trials and tribulations
01 July, 2011 by Tim DeanThe last 12 months has been one of tremendous ups and downs for Australian biotechnology companies.
BIO 2011 report: Australian biotechnology spotlight
30 June, 2011 by Tim DeanALS surveys some of the big movers and shakers in the Australian biotechnology industry from the year that’s past and the year ahead.
Starpharma brings its novel technology to leading cancer treatment
29 June, 2011 by Tim DeanStarpharma (ASX:SPL) is conducting pre-clinical studies on popular chemotherapy treatment, docaetaxel, reformulated using the company’s dendrimer technology.
BIO 2011: Kim Carr on the importance of biotechnology
29 June, 2011 by Staff WritersSenator Kim Carr, Minister for Innovation, Industry, Science and Research, says biotechnology is central to Labor’s agenda.
R&D Tax Credit positions Australian biotechs for Asian boom
28 June, 2011 by Tim DeanThe R&D Tax Credit will bring more research funding to Australia to capitalise on the burgeoning Asian health market, says Barry Thomas from Cook Medical.
Australian biotechs front up at BIO 2011
27 June, 2011 by Staff WritersOver 30 Australian life sciences organisations and biotechnology companies will be present at BIO 2011, which launches today.
BIO 2011 biotech profile: Patrys, from theory to practice
24 June, 2011 by Tim DeanTaking Patrys’ antibody technology from the lab to the clinic was no small feat. Now those hurdles have been overcome, Patrys is looking towards the future.
BIO 2011 biotech profile: Patrys
23 June, 2011 by Tim DeanPatrys has overcome substantial hurdles to show its innovative approach to cancer treatment using natural antibodies is ready for the big leagues.
CSL receives official warning from FDA
22 June, 2011 by Tim DeanThe US Food and Drug Administration has issued an official warning letter to CSL listing concerns about the manufacture of influenza vaccine, Afluria.
AusBiotech supports research exemption in patent reform Bill
22 June, 2011 by Tim DeanAusBiotech has welcomed the research exemption from patent infringement in Australia’s intellectual property reform bill introduced into Parliament today.
BIO 2011 biotech profile: Mesoblast’s vision from the top
21 June, 2011 by Tim DeanMesoblast CEO, Professor Silviu Itescu , was instrumental in cutting the historic billion-dollar deal with Cephalon. He speaks to ALS about how he did it.
BIO 2011 biotech profile: Mesoblast
20 June, 2011 by Tim DeanMesoblast has been making great strides in its stem cell technology over the past several years, and it all paid off with a game changing deal cut with US pharma Cephalon late last year.
R&D Tax Credit will boost small biotechs
17 June, 2011 by Tim DeanThe R&D Tax Credit will give a much needed boost to small cap biotechs, says Karen Sinclair, past president of LESANZ.
R&D Tax Credit (finally) gets the go ahead
15 June, 2011 by Tim DeanCrossbench support has paved the way for the beleaguered R&D Tax Credit to pass the Senate in the next session, coming into effect as of 1 July 2011.
QRxPharma to file NDA within two months
15 June, 2011 by Staff WritersAfter completing a phase III safety trial of analgesic MoxDuo IR QRxPharma (ASX: QRX) is winding up for its New Drug Application within two months time.
